|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1616 H Street, N.W. |
Address2 | Suite 902 |
City | Washington |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 11025-12
|
||||||||
|
6. House ID# 318530000
|
TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Thair Phillips, President |
Date | 10/19/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code RET
16. Specific lobbying issues
Support H.R. 1086, the CPI for Seniors Act
Support the Social Security and Medicare Protection Act (now H.R. 1630)
Oppose any effort to establish a chained-CPI to determine annual Social Security COLAs.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thair |
Phillips |
|
President |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Support the Social Security and Medicare Protection Act (now H.R. 1630).
Support full and increased funding for the Low Income Energy Assistance Program (LIHEAP) for FY 2012 (at least $5.1 billion).
Support full and increased funding for National Institutes of Health (NIH) and theNational Institute on Aging (NIA).
Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid
Oppose any effort to establish a chained-CPI to determine annual Social Security COLAs.
Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis.
Oppose all harmful cuts to Medicare designed to provide "deficit reduction."
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thair |
Phillips |
|
President |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Support the speedy implementation of the National Alzheimer's Project Act (NAPA) by HHS, and support Leaders Engaged on Alzheimer's Disease (LEAD) recommendations as to how to proceed.
Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals.
(Support H.R. 1159 and H.R. 1186)
Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs.
Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed.
Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid.
Support all legislative and regulatory action to modernize the FDA and to speed new cures and therapies to patients.
Support the Preservation of Access to Osteoporosis Testing for Medicare Benificiaries Act of 2011 (S. 1096, H.R. 2020)
Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis.
17. House(s) of Congress and Federal agencies Check if None
Health & Human Services - Dept of (HHS), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thair |
Phillips |
|
President |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Support American Society of Consultant Pharmacists and "Short Cycle Dispensing Coalition" recommendations regarding the delay and study of new long-term care pharmacy dispensing rules and the impact of those rules on Medicare and Medicaid patients.
Support H.R. 1055, the Part D Off-Label Prescription Drug Parity Act.
Continue to oppose cuts to Medicare benefits, and continue to oppose the Independent Payment Advisory Board (IPAB).
Support Medicare Access for Patients Rx (MAPRx) recommendations to Centers for Medicare and Medicaid Services (CMS) all regarding Medicare Part D. Those MAPRx recommendations are in regard to:
Improved beneficiary protections; Better, more transparent Specialty Tier guidance including the threshold for inclusion on this tier and the inclusion of data for newly approved drugs; New, more realistic co-pay thresholds; Automatic disenrollment from Special Needs Plans; Proposed plan rating criteria; and Approval of six-tier formularies. These are in addition to MAPRx concerns regarding: The Part D Medicare appeals process and the handling of enrollee complaints; Drug dispensing rules for Part D beneficiaries in long-term care facilities; the Authority to deny bids and potential additional restrictions; and Compound Drug Policy.
Support repeal of IPAB (H.R. 452).
Support changes to the Medicare Shared Savings Program: Accountable Care Organization (ACO) proposed regulations, to provide additional safeguards to guarantee patient access to needed care, and to ensure that ACO's support the adoption of new treatments and cures for patients. Also support the addition of new Alzheimer's disease focused ACO quality measures, new ACO measures of provider evidence of competency in Geriatrics and Dementia, as well as a guarantee that Alzheimer's and Dementia patients under ACO care will have access to the newest pharmaceutical and biological treatments.
Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals.
(Support H.R. 1159 and H.R. 1186)
Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid
Support the Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 (S. 1096 and H.R. 2020)
Support MAPRx suggestions to CMS on Medicare Part D Prescription Drug Program regarding new beneficiary-friendly point-of-sale notices that address problems in filling prescriptions and clear, instructive remedies for beneficiaries.
Oppose proposals that would reduce payments to providers of drugs and biologics under Medicare Part B.
Oppose proposals to increase Medicare Part D cost-sharing, raise Part D coinsurance, and/or freeze income thresholds.
Oppose efforts to require Medicaid-type drug rebates from any Medicare Part D providers and all other kinds of mandated or negotiated Part D price controls that will harm beneficiaries and increase costs in other areas of Medicare.
Support efforts to focus Medicare cost-saving efforts on eliminating improper payments, waste, fraud, and abuse first -- before cutting benefits, cutting payments to providers, or raising premium and coinsurance costs for beneficiaries.
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thair |
Phillips |
|
President |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Support the Motor Vehicle Owners Right to Repair Act (now H.R. 1449).
Support Access to Repair Parts legislation.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thair |
Phillips |
|
President |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |